Peptide T in the treatment of painful distal neuropathy associated with AIDS: Results of a placebo-controlled trial

Neurology

Volumn 47, Issue 5, 1996, Pages 1254-1259

  Simpson, D M ^a,b   Dorfman, D ^b   Olney, R K ^c   McKinley, G ^d   Dobkin, J ^e   So, Y ^c   Berger, J ^f   Ferdon, M B ^g   Friedman, B ^g   Gerits, P ^a   Goldbaum, L ^c   Burns, S ^d   Kolatch, ^d   Stern, Y ^e   Britton, C ^e   Wade, M ^e   Winfield, D ^f   Pall, L ^f   Portegies, ^h  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Department of Neurology ^*

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^e Saint luke'S/Roosevelt Hospital ^*  (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g Guidelines Inc

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CD4 ANTIGEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NOSE SPRAY; PARACETAMOL; PEPTIDE T; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRANASAL DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVE CONDUCTION; NEURALGIA; NEUROPSYCHOLOGICAL TEST; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURAL NERVE; TREATMENT OUTCOME;

EID: 10344250944     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.5.1254     Document Type: Article

References (20)

1. Simpson DM, Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med 1994;121:769-785.
2. Simpson DM, Olney RK. Peripheral neuropathies associated with HIV infection. Neurol Clin 1992;10:685-711.
3. Bacellar H, Muñoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: multicenter AIDS cohort study, 1985-1992. Neurology 1994;44:1892-1900.
4. So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with AIDS. Prevalence and clinical features from a population based survey. Arch Neurol 1988;45: 945-948.
5. Griffin JW, Crawford TO, Tyor WR, et al. Predominantly sensory neuropathy in AIDS: distal axonal degeneration and unmyelinated fiber loss [abstract]. Neurology 1991;41(suppl 1): 374.
6. Pert CB, Hill JM, Ruff MR, et al. Octapeptides deduced from neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T cell infectivity. Proc Natl Acad Sci USA 1986;83:9254-9258.
7. Brenneman DE, Buzy JM, Ruff MR, Pert CB. Peptide T sequences prevent neuronal cell death produced by the envelope protein (gp120) of the HIV virus. Drug Dev Res 1988;15:361-369.
8. Pert CB, Smith CC, Ruff RM, Hill SM. AIDS and its dementia as neuropeptide disorder: role of VIP receptor blockade by HIV envelope. Ann Neurol 1988;23:571-573.
9. Kleinerman ES, Lachman LB, Knowles RD, Snyderman R, Ciancolo GJ. A synthetic peptide homologous to the envelope proteins of retroviruses inhibits monocyte-mediated killing by inactivating interleukin 1. J Immunol 1987;139:2329-2337.
10. Brennenman DE, Westbrook G, Fitzgerald SP, et al. Neuronal cell killing by the envelope protein of HIV and its prevention by vasointestinal peptide. Nature 1988;335:639-642.
11. Wesselingh SL, Power C, Fox R, et al. Cytokine MRNA expression in HIV-associated neurological disease [abstract]. Neurology 1993;43(suppl 2):291A.
12. Bridge TP, Haseltine PNR, Parker ES, et al. Improvement in AIDS patients on Peptide T. Lancet 1989;2:226-227.
13. Ruff MR, Smith C, Kingan T, et al. Pharmacokinetics of Peptide T in patients with AIDS. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:791-801.
14. Wetterberg L, Alexius B, Saaf J, Sonnenberg A, Briton S, Pert CB. Peptide T in treatment of AIDS [letter]. Lancet 1987;1: 159.
15. Haseltine P, Eaton E, Buchsbaum M, et al. Effects of Peptide T on AIDS dementia complex (ADC): correlation of PET scans and cognitive domains [abstract]. Seventh International Conference on AIDS. Florence, 1991.
16. MeFadden DK, Doob PR. The role of Peptide T in the palliation of HIV-1-related painful peripheral neuropathy [abstract]. Seventh International Conference on AIDS. Florence, 1991.
17. Gracely RH, McGrath P, Dubner R. Ratio scales of sensory and affective verbal pain descriptors. Pain 1978;5:5-18.
18. Cohen J. Statistical power for the behavioral sciences. Hillsdale, NJ: Erlbaum, 1986.
19. National Institutes of Mental Health. Analyses of Peptide T efficacy on neuropsychological performance in HIV seropositive individuals with cognitive impairment. Press release: October 24, 1995.
20. Morse EV, Simon P, Coburn P, Hyslop N, Greenspan D, Balson P. Determinants of subject compliance within an experimental anti-HIV drug protocol. Soc Sci Med 1991;32:1161-1167.